CSL Ltd Annual Report 2019

16 Donor management Since 2011, CSL Plasma, a division of CSL Behring, has grown to become one of the largest plasma collection networks in the world, providing human plasma to CSL Behring for the manufacture and distribution of plasma protein biotherapeutics. Its expanded laboratory and logistics operations have increased CSL Plasma’s testing and storage capacity to meet the growing need for plasma-derived therapies. CSL Plasma has over 235 collection centres globally (US, Germany, Hungary and China) with plasma testing laboratories and logistics centres in the US, Germany and China along with a saline and sodium citrate manufacturing facility in the US. For our donors, CSL Plasma has developed the most efficient processes and systems that focus on donor and plasma safety, along with donor satisfaction. Efficient and safe donor management contributes to our success by ensuring a supply of rawmaterial which we use in our biotherapy manufacture. Over the reporting period, more than a million surveys completed by our plasma donors indicated 99% would be willing to donate again and 97% would be willing to refer a friend to donate. Focus on efficiency, standardised manufacturing processes and integrated supply chain To meet the global demand for CSL’s lifesaving medicines, we drive an integrated enterprise approach to manufacturing across our business – with the goal to enhance our production capabilities across all of our product lines. The underlying strategy is to spread risk across our end-to- end manufacturing and supply network and to utilise each node of the network to its utmost potential. We focus on safety, quality and efficiency as core foundations to reliable and high-quality supply. Development of an end-to-end enterprise network strategy was commenced over the reporting year. This will ensure tighter integration across the network, better utilisation of assets, diversification of risk and improvements in supply reliability and will deliver benefits in the years to come. Currently projects are underway to improve yield and drive operational efficiencies such as an initiative targeting higher yielding immunoglobulin processes that will positively impact PRIVIGEN ® plants in Bern, Switzerland, and Broadmeadows, Australia. PACE, CSL Behring’s end- to-end process transformation, is delivering improved processes which are already demonstrating more efficient and repeatable processes applied consistently across all manufacturing plants. For CSL Plasma, the collection of vital human-derived plasma for the development of lifesaving products is industry leading. With careful localised management of operations, including donor remuneration, CSL Plasma facilities minimise donor time via integrated donor management systems including electronic biometric identification and check-in, streamlined floor layouts and an operational excellence approach driving a cohesive culture of efficiency and teamwork. CSL Plasma donor profile The socio-demographic background of CSL Plasma donors in the US is very diverse. Based on self-reported survey data (1 July 2018 to 27 June 2019), CSL Plasma donors related their occupational status (90% of donors reported their occupational status): –– 51% described themselves as working full-time; –– 24% described themselves as unemployed, inclusive of full-time parents, donors who are not looking for work or the unemployed; –– 15% described themselves as part-time; –– 10% described themselves as students; and –– 9% described themselves as other (e.g., military, retired). 99% of plasma donors are willing to donate again. 97% of plasma donors are willing to refer a friend to a centre. CSL Limited Annual Report 2019 24 Global Reach and Impact